Vivani Medical, Inc.
VANI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.19 | -0.01 | 0.05 | 0.00 |
| FCF Yield | -33.46% | -47.40% | -58.86% | -6.50% |
| EV / EBITDA | -2.80 | -2.05 | 0.61 | -13.63 |
| Quality | ||||
| ROIC | -66.83% | -65.04% | -46.93% | -256.85% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.89 | 0.92 | 1.35 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 13.19% | -28.55% | -65.99% | -48.31% |
| Safety | ||||
| Net Debt / EBITDA | -0.04 | -0.00 | 2.30 | 0.03 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -745.51 | -554.15 | -1,127.57 | -297.29 |